Latest Regulatory Process News

Xstate Resources has appointed joint lead managers for a $2-3 million capital raise aimed at re-compliance with ASX listing rules and trading reinstatement. The company also plans a key acquisition pending shareholder approval.

Larvotto Resources has secured preliminary regulatory approval to extend mining at its Hillgrove Gold-Antimony Mine through 2026, paving the way for project financing and production ramp-up.

C29 Metals has secured Category 4 exploration approval for its newly granted eastern tenement in Kazakhstan, advancing its multi-mineral project and gaining strong local community support.

Diatreme Resources’ Northern Silica Project has been awarded Major Project Status by the Australian Government, marking a pivotal step in advancing critical minerals development in Queensland. This designation streamlines federal approvals and supports the project’s role in the clean energy supply chain.

ASPI Isotopes Inc. has proposed a scheme to acquire all Renergen shares at a 41.3% premium, aiming to create a global critical materials powerhouse. The deal, subject to shareholder and regulatory approval, will delist Renergen from multiple exchanges.

Pure Hydrogen Corporation has secured a 15-year Potential Commercial Area approval and extended its ATP 927 permit for the Windorah Gas Project, marking a critical regulatory milestone ahead of its planned spinout.

Firebrick Pharma has published its pivotal Phase 3 trial results for Nasodine nasal spray, confirming its effectiveness and safety in treating the common cold, especially when used early.

The Takeovers Panel has imposed interim restrictions on shares issued in Emu NL's recent placement, halting any trading by subscribers pending further review.

Echo IQ’s application for a key US procedural code was rejected but the company plans a swift resubmission, maintaining confidence in its US commercial rollout.

Yowie Group Ltd has firmly rejected the validity of director removal and nomination notices purportedly from Keybridge Capital, while confirming its status as Keybridge’s largest creditor with over $6.6 million owed. The company also detailed a recent share placement amid ongoing regulatory scrutiny.

Askari Metals offers holders of expired AS2O options a priority issue of new options, while advancing due diligence on a promising Ethiopian gold project.

Paradigm Biopharmaceuticals has secured centralised US ethics approval for its pivotal Phase 3 trial of injectable pentosan polysulfate sodium (iPPS) targeting moderate to severe knee osteoarthritis, setting the stage for patient enrolment in Q3 2025.